Literature DB >> 2266363

Effect of nicardipine on somatosensory evoked potentials in patients with acute cerebral infarction.

L P Yao1, D Y Ding.   

Abstract

We evaluated the effect of nicardipine, a calcium channel blocker, on somatosensory evoked potentials (SEP) in 26 patients with acute cerebral infarction. Post treatment, 58% (15/26) of the N20 and P25 latencies were prolonged in the affected hemispheres; 8% (2/26) were shortened; and 35% (9/26) did not change. The mean N20 and P25 latencies were significantly prolonged two hours post treatment in the affected hemisphere (N20, P less than 0.01, P25 P less than 0.01). Nicardipine (Ni) had no effect on SEP components in the intact hemispheres. Seventy five per cent of the 12 patients with hypertension had a decrease in blood pressure (BP) after taking nicardipine, but there were no undesirable side effects or worsening of neurological signs. Our study demonstrates that nicardipine prolongs the latencies of short-latency components of SEP in the affected hemisphere after acute ischaemic stroke and also decreases BP. These observations suggest that nicardipine therapy might impair neuronal function in the ischaemic zone.

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 2266363      PMCID: PMC488243          DOI: 10.1136/jnnp.53.10.844

Source DB:  PubMed          Journal:  J Neurol Neurosurg Psychiatry        ISSN: 0022-3050            Impact factor:   10.154


  26 in total

1.  Efficacy and mechanism of action of a calcium channel blocker after global cerebral ischemia in rats.

Authors:  J C Grotta; L C Pettigrew; D Rosenbaum; C Reid; H Rhoades; D McCandless
Journal:  Stroke       Date:  1988-04       Impact factor: 7.914

2.  Nicardipine reduces ischemic brain injury. Magnetic resonance imaging/spectroscopy study in cats.

Authors:  J Kucharczyk; W Chew; N Derugin; M Moseley; C Rollin; I Berry; D Norman
Journal:  Stroke       Date:  1989-02       Impact factor: 7.914

3.  Evoked potentials in the clinical neurosciences.

Authors:  R P Greenberg; T B Ducker
Journal:  J Neurosurg       Date:  1982-01       Impact factor: 5.115

4.  Failure of flunarizine to improve cerebral blood flow or neurologic recovery in a canine model of complete cerebral ischemia.

Authors:  L A Newberg; P A Steen; J H Milde; J D Michenfelder
Journal:  Stroke       Date:  1984 Jul-Aug       Impact factor: 7.914

5.  Effects of cerebroprotective agents on cerebral blood flow and on postischemic energy metabolism in the rat brain.

Authors:  G W Bielenberg; T Beck; D Sauer; M Burniol; J Krieglstein
Journal:  J Cereb Blood Flow Metab       Date:  1987-08       Impact factor: 6.200

6.  Flunarizine reduces cerebral infarct size after photochemically induced thrombosis in spontaneously hypertensive rats.

Authors:  J Van Reempts; B Van Deuren; M Van de Ven; F Cornelissen; M Borgers
Journal:  Stroke       Date:  1987 Nov-Dec       Impact factor: 7.914

7.  The therapeutic value of nimodipine in experimental focal cerebral ischemia. Neurological outcome and histopathological findings.

Authors:  I M Germano; H M Bartkowski; M E Cassel; L H Pitts
Journal:  J Neurosurg       Date:  1987-07       Impact factor: 5.115

8.  A controlled trial of nimodipine in acute ischemic stroke.

Authors:  H J Gelmers; K Gorter; C J de Weerdt; H J Wiezer
Journal:  N Engl J Med       Date:  1988-01-28       Impact factor: 91.245

9.  The effects of a calcium antagonist, nimodipine, upon physiological responses of the cerebral vasculature and its possible influence upon focal cerebral ischaemia.

Authors:  R J Harris; N M Branston; L Symon; M Bayhan; A Watson
Journal:  Stroke       Date:  1982 Nov-Dec       Impact factor: 7.914

10.  Somatosensory evoked potentials in lacunar syndromes.

Authors:  G Abbruzzese; G Bino; D Dall'Agata; M Morena; A Primavera; E Favale
Journal:  J Neurol       Date:  1988-05       Impact factor: 4.849

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.